HCRT and colonic neoplasm: BALB/c mice were subcutaneously injected with murine MSS CT26 colon tumor cells (28), followed by treatment with rat IgG, anti-TIGIT mAb (10 mg/kg), OX (1.5 mg/kg) or anti-TIGIT mAb plus OX on day 8 post-tumor challenge (Figure 1A).